Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Brain cancer

Hyaluronan-mediated motility receptor (RHAMM; CD168)

Human samples and mouse studies suggest inhibiting RHAMM could help treat glioblastoma. Analysis of human glioma samples revealed higher RHAMM expression than that in normal brain tissue. In mice bearing human glioblastoma cells, shRNA knockdown of RHAMM decreased tumor-forming potential compared with no alteration, whereas overexpression of RHAMM increased expression of stem cell markers and tumor growth. Next steps include testing the effects of chemical compounds that inhibit RHAMM expression in glioma stem cells.

SciBX 7(19); doi:10.1038/scibx.2014.552
Published online May 15, 2014

Patent and licensing status undisclosed

Tilghman, J. et al. Cancer Res.; published online April 7, 2014;
doi:10.1158/0008-5472.CAN-13-2103
Contact: Mingyao Ying, The Johns Hopkins University School of Medicine, Baltimore, Md.
e-mail:

ying@kennedykrieger.org